Welcome to our dedicated page for Belite Bio news (Ticker: BLTE), a resource for investors and traders seeking the latest updates and insights on Belite Bio stock.
Belite Bio, Inc. reports clinical and regulatory developments for tinlarebant, an oral investigational therapy for degenerative retinal diseases. The company focuses on Stargardt disease type 1 (STGD1) and geographic atrophy in advanced dry age-related macular degeneration, with a program designed to reduce accumulation of bisretinoid toxins in the eye.
Recurring updates include DRAGON and DRAGON II Stargardt disease studies, PHOENIX geographic atrophy development, FDA interactions, scientific meeting presentations, investor-conference appearances, financial results, annual Form 20-F availability, and capital actions involving American Depositary Shares. Company news also covers corporate updates for a foreign private issuer whose securities trade under BLTE.
Belite Bio, Inc (NASDAQ: BLTE) is set to host a KOL event on October 27, 2022, focusing on LBS-008 (Tinlarebant), its lead oral treatment for Stargardt Disease and Dry AMD. Dr. Quan Dong Nguyen from Stanford will present one-year interim data from a Phase 1b/2 trial. Tinlarebant, aimed at reducing toxic retinal byproducts, has received Fast Track and Orphan Drug Designations. With over 11 million Dry AMD patients in the U.S. and significant global healthcare costs, advancements in treatments like LBS-008 are crucial for eye health.
Belite Bio (NASDAQ: BLTE) announced promising 12-month results from its Phase 2 study of LBS-008 (Tinlarebant) in adolescents with Stargardt Disease (STGD1). The data revealed safety and tolerability, with 92.3% of subjects showing no atrophic lesions. A significant percentage reported stabilization in visual acuity and retinal thickness. Notably, the average lesion growth rate was only 0.03 mm2/year, indicating potential to slow disease progression compared to historical data. The next data readout is anticipated in Q2 2023.
Belite Bio (NASDAQ: BLTE) announced the presentation of 1-year interim data from its 2-year Phase 1b/2 trial of LBS-008 for adolescent STGD1 at the American Academy of Ophthalmology Annual Meeting, scheduled for October 1, 2022, in Chicago. This novel oral therapy aims to prevent the accumulation of toxins in the eye associated with STGD1 and Dry AMD. LBS-008 has received multiple regulatory designations, including Fast Track and Orphan Drug in the U.S. and Europe, highlighting its potential as a treatment for currently untreatable eye diseases.
Belite Bio has received approval from China's National Medical Products Administration to initiate the Phase 3 clinical trial of LBS-008, an oral treatment for Stargardt disease (STGD1). The DRAGON trial, which is already underway globally, aims to evaluate the safety and efficacy of LBS-008 in adolescent STGD1 patients. Preliminary Phase 2 results show that 61.5% of participants gained visual acuity. LBS-008 has also been granted Fast Track and Orphan Drug Designations due to its potential to address significant unmet medical needs in retinal diseases.
Belite Bio has initiated a Phase 3 clinical trial for its lead asset, LBS-008 (Tinlarebant), targeting Stargardt Disease (STGD1), a degenerative eye condition with no current treatments. This randomized, double-masked, placebo-controlled study involves sites in multiple countries including the U.S. and U.K. LBS-008 has received fast track and orphan drug designations. Preliminary Phase 2 trial results show 61.5% of adolescent participants experienced visual acuity improvements, prompting optimism about its potential for STGD1 and Dry AMD treatment.
Belite Bio (NASDAQ: BLTE) reported significant advancements in its lead asset, LBS-008 (Tinlarebant), targeting Stargardt disease and Dry AMD. The ongoing Phase 3 trial (DRAGON) has commenced in multiple countries, enrolling several patients. LBS-008 has received fast track, rare pediatric disease, and orphan drug designations. Financially, as of June 30, 2022, Belite holds $48.7 million in cash, with a reduced net loss of $3.5 million compared to $4.7 million in the previous year.
Belite Bio, a biopharmaceutical company focused on untreatable eye diseases, will host a conference call on August 11, 2022, at 4:30 PM ET to discuss financial results for the first half of 2022.
The results will be released on August 10, 2022. Investors can join the call through a webcast or phone registration. The company is developing treatments for conditions like dry AMD and Stargardt disease.
Belite Bio (NASDAQ: BLTE) has submitted an IND application to the FDA for LBS-008, an oral treatment for Stargardt disease (STGD1), currently with no FDA-approved therapies. This drug, a retinol binding protein 4 antagonist, aims to reduce toxic vitamin A byproducts implicated in vision loss. Two ongoing trials, including a Phase 2 and a global Phase 3 (DRAGON), have shown promising initial results, with 61.5% of Phase 2 participants gaining visual acuity. The company has received fast track, rare pediatric disease, and orphan drug designations for LBS-008.
Belite Bio, a clinical stage biopharmaceutical company focused on treating eye diseases, announced that the underwriters for its IPO exercised part of their over-allotment option. This resulted in the sale of an additional 772,091 American Depositary Shares (ADS) at $6.00 each, raising total gross proceeds to approximately $40.63 million. The funds will support the Phase 3 trial of LBS-008 for Stargardt disease and further development for dry AMD, alongside working capital needs. The SEC had declared the registration statement effective earlier in April 2022.
Belite Bio (Nasdaq: BLTE) announced interim results from its Phase 1b/2 study of LBS-008 for adolescent Stargardt disease (STGD1) at the ARVO 2022 meeting. The treatment displayed an acceptable safety profile, with mild adverse events, and a majority of participants showing stabilized or improved visual acuity. LBS-008 effectively reduced RBP4 levels by 80-90%. The study's extension phase will involve ongoing evaluation over two years, highlighting its potential for treating currently untreatable eye diseases.